Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07MON
|
|||
| Former ID |
DNC003727
|
|||
| Drug Name |
ONAPRISTONE
|
|||
| Synonyms |
Onapristone; 96346-61-1; Onapristone [INN]; ZK-98299; Onapristonum [Latin]; Onapristona [Spanish]; UNII-H6H7G23O3N; ZK 299; CCRIS 6530; ZK 98299; ZK-299; H6H7G23O3N; C29H39NO3; Onapristone (INN); Onapristonum; Onapristona; (8S,11R,13R,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-, (11-beta,13-alpha,17-alpha)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 2 | [1] | |
| Company |
Context Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H39NO3
|
|||
| Canonical SMILES |
CC12CC(C3=C4CCC(=O)C=C4CCC3C1CCC2(CCCO)O)C5=CC=C(C=C5)N(C)C
|
|||
| InChI |
1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1
|
|||
| InChIKey |
IEXUMDBQLIVNHZ-YOUGDJEHSA-N
|
|||
| CAS Number |
CAS 96346-61-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Progesterone receptor (PGR) | Target Info | Modulator | [2] |
| KEGG Pathway | Oocyte meiosis | |||
| Progesterone-mediated oocyte maturation | ||||
| Pathway Interaction Database | Cellular roles of Anthrax toxin | |||
| Reactome | Nuclear signaling by ERBB4 | |||
| Nuclear Receptor transcription pathway | ||||
| WikiPathways | Ovarian Infertility Genes | |||
| Signaling by ERBB4 | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Context Therapeutics. | |||
| REF 2 | Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999 Feb;35(2):214-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.